FRONT MED-PRC 润色咨询

Frontiers of Medicine

出版年份:2014 年文章数:400 投稿命中率: 开通期刊会员,数据随心看

出版周期:Quarterly 自引率:3.6% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2286522, encodeId=009c22865228c, content=2024.6.8提交初稿,用期刊官网模板排版,参考文献通过 EndNote 导入「Vancouver 格式」,原始数据按「实验分组 - 检测指标 - 重复次数」整理成 Excel 附件<br>6.8-6.15With Editor(编辑初审)7 天收到编辑邮件:确认研究方向符合期刊范畴,数据完整性达标,无需格式修改<br>Under Review(外审)用了20 天<br>系统显示分配2位审稿人<br>7.06Major Revision(大修意见)审稿人1提了3个意见<br>7.22返修准备<br>7.23-7.30Revision Submitted~Under Review返修稿按要求标注修改位置附 1200 字逐点回复信<br>8.17With Editor(编辑终审)<br>期间主动邮件询问进度(模板:简述稿件编号 + 修改亮点 + 礼貌问询),编辑次日回复「正汇总意见」<br>8.19Accept(录用通知)<br>收到录用邮件,附带版面费缴费链接(3295 美元,OA 期刊常规标准), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722175, createdTime=Mon Oct 27 23:28:20 CST 2025, time=2025-10-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2277604, encodeId=ff4f22e760441, content=有点惨,期刊官方说中位数78天给结果,我投完苦等,实际超半年才有信儿。<br>说我研究方向和期刊要求有点偏差,纯基础分子机制,和临床关联少,直接给我拒了。<br>而且现在对数据要求超严,反馈说我原始数据整理得不够清晰规范,另外,投稿格式要严格按官网指南来,我就因为参考文献格式不对还被挑刺了。<br>大家投稿前一定要多注意这些还有一些小细节的东西,别像我一样吃亏。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722169, createdTime=Sun Aug 17 23:09:09 CST 2025, time=2025-08-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2264257, encodeId=2fd0226425eaf, content=有注册账户时,注册账户报错的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18875624576, createdName=ms5000001999881653, createdTime=Fri May 09 22:03:52 CST 2025, time=2025-05-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2265267, encodeId=1a3e226526edd, content=偏重的研究方向:肿瘤<br>经验分享:记录投稿过程 2025.05.08投稿 然后awaiting admin processing 0516 Awaiting Reviewer Selection, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcd68820091, createdName=想要ACCEPT, createdTime=Fri May 16 09:41:11 CST 2025, time=2025-05-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=588271, encodeId=20205882e1d3, content=请问有人最近投稿的嘛??这个杂志是不是很慢,Awaiting Admin Processing这个过程要多久???10天正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=500, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8652460850, createdName=12418dafm09(暂无昵称), createdTime=Mon Apr 06 13:28:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2254202, encodeId=0fdd225420274, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:医学;前沿;医学综合<br>经验分享:1.24投稿, 2.14修回,一个接受,一个小修 修改2周 2.27修改好上传 2.28接受 厉害了我的哥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb5a8346436, createdName=ms8000000905145026, createdTime=Sun Mar 02 11:57:38 CST 2025, time=2025-03-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2173019, encodeId=1ffe21e301990, content=投稿的时候迷茫绝望过,一次次的来到这个地方寻求帮助,现在把投稿过程贴出来,留给需要的人<br>2023.7.21 submit<br>2023.7.24 awaiting reviewer selection<br>2023.7.26 awaiting reviewer invitation<br> awaiting reviewer assignment<br>2023.8.5 awaiting reviewer scores<br>2023.8.9 awaiting AE recommendation<br>2023.8.23 reconsider (re-review) after major revision<br>2023.10.19 submit<br> awaiting admin checklist<br> awaiting reviewer assignment<br>2023.10.31 awaiting admin processing<br> major revision<br>2023.11.7 submit<br> awaiting admin checklist<br>202311.14 awaiting AE recommends<br>2023.11.16 awaiting ElC decision<br>2023.12.4 accept<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=345, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50061907645, createdName=ms4255114797740350, createdTime=Tue Dec 05 10:36:23 CST 2023, time=2023-12-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183765, encodeId=6f9f2183e65b9, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享:兄弟们,中了!!!投稿到接受不到两个月,一篇综述,现在就等见刊!!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5af09148065, createdName=ms7000000774997479, createdTime=Wed Jan 24 22:39:26 CST 2024, time=2024-01-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=914698, encodeId=4ebf91469861, content=投稿命中率:50.0<br>偏重的研究方向:医学<br>经验分享:有好文章赶快投。2021年上4分。2022年上10分。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=456, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1825439058, createdName=鬼混过日子, createdTime=Fri Jan 08 18:50:37 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152059, encodeId=945f215205989, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向:医学<br>经验分享:有没有最近在投的大佬,两轮修稿,已经awaiting EIC decision2个星期了,一般需要多久给最终决定呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/NqoPtUG8c3KoicPDw9ukvZno5y3ibqsdVNWCkwiangfxiaP2pJpicKKPVt393X5eMnkCZicpb6RLhx1ia4du74T91e3ibw/132, createdBy=50932398583, createdName=Jovanny, createdTime=Thu Aug 10 08:42:58 CST 2023, time=2023-08-10, status=1, ipAttribution=上海)]
    2025-10-27 ms8000002977722175 来自北京

    2024.6.8提交初稿,用期刊官网模板排版,参考文献通过 EndNote 导入「Vancouver 格式」,原始数据按「实验分组 - 检测指标 - 重复次数」整理成 Excel 附件
    6.8-6.15With Editor(编辑初审)7 天收到编辑邮件:确认研究方向符合期刊范畴,数据完整性达标,无需格式修改
    Under Review(外审)用了20 天
    系统显示分配2位审稿人
    7.06Major Revision(大修意见)审稿人1提了3个意见
    7.22返修准备
    7.23-7.30Revision Submitted~Under Review返修稿按要求标注修改位置附 1200 字逐点回复信
    8.17With Editor(编辑终审)
    期间主动邮件询问进度(模板:简述稿件编号 + 修改亮点 + 礼貌问询),编辑次日回复「正汇总意见」
    8.19Accept(录用通知)
    收到录用邮件,附带版面费缴费链接(3295 美元,OA 期刊常规标准)

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2286522, encodeId=009c22865228c, content=2024.6.8提交初稿,用期刊官网模板排版,参考文献通过 EndNote 导入「Vancouver 格式」,原始数据按「实验分组 - 检测指标 - 重复次数」整理成 Excel 附件<br>6.8-6.15With Editor(编辑初审)7 天收到编辑邮件:确认研究方向符合期刊范畴,数据完整性达标,无需格式修改<br>Under Review(外审)用了20 天<br>系统显示分配2位审稿人<br>7.06Major Revision(大修意见)审稿人1提了3个意见<br>7.22返修准备<br>7.23-7.30Revision Submitted~Under Review返修稿按要求标注修改位置附 1200 字逐点回复信<br>8.17With Editor(编辑终审)<br>期间主动邮件询问进度(模板:简述稿件编号 + 修改亮点 + 礼貌问询),编辑次日回复「正汇总意见」<br>8.19Accept(录用通知)<br>收到录用邮件,附带版面费缴费链接(3295 美元,OA 期刊常规标准), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722175, createdTime=Mon Oct 27 23:28:20 CST 2025, time=2025-10-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2277604, encodeId=ff4f22e760441, content=有点惨,期刊官方说中位数78天给结果,我投完苦等,实际超半年才有信儿。<br>说我研究方向和期刊要求有点偏差,纯基础分子机制,和临床关联少,直接给我拒了。<br>而且现在对数据要求超严,反馈说我原始数据整理得不够清晰规范,另外,投稿格式要严格按官网指南来,我就因为参考文献格式不对还被挑刺了。<br>大家投稿前一定要多注意这些还有一些小细节的东西,别像我一样吃亏。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722169, createdTime=Sun Aug 17 23:09:09 CST 2025, time=2025-08-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2264257, encodeId=2fd0226425eaf, content=有注册账户时,注册账户报错的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18875624576, createdName=ms5000001999881653, createdTime=Fri May 09 22:03:52 CST 2025, time=2025-05-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2265267, encodeId=1a3e226526edd, content=偏重的研究方向:肿瘤<br>经验分享:记录投稿过程 2025.05.08投稿 然后awaiting admin processing 0516 Awaiting Reviewer Selection, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcd68820091, createdName=想要ACCEPT, createdTime=Fri May 16 09:41:11 CST 2025, time=2025-05-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=588271, encodeId=20205882e1d3, content=请问有人最近投稿的嘛??这个杂志是不是很慢,Awaiting Admin Processing这个过程要多久???10天正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=500, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8652460850, createdName=12418dafm09(暂无昵称), createdTime=Mon Apr 06 13:28:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2254202, encodeId=0fdd225420274, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:医学;前沿;医学综合<br>经验分享:1.24投稿, 2.14修回,一个接受,一个小修 修改2周 2.27修改好上传 2.28接受 厉害了我的哥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb5a8346436, createdName=ms8000000905145026, createdTime=Sun Mar 02 11:57:38 CST 2025, time=2025-03-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2173019, encodeId=1ffe21e301990, content=投稿的时候迷茫绝望过,一次次的来到这个地方寻求帮助,现在把投稿过程贴出来,留给需要的人<br>2023.7.21 submit<br>2023.7.24 awaiting reviewer selection<br>2023.7.26 awaiting reviewer invitation<br> awaiting reviewer assignment<br>2023.8.5 awaiting reviewer scores<br>2023.8.9 awaiting AE recommendation<br>2023.8.23 reconsider (re-review) after major revision<br>2023.10.19 submit<br> awaiting admin checklist<br> awaiting reviewer assignment<br>2023.10.31 awaiting admin processing<br> major revision<br>2023.11.7 submit<br> awaiting admin checklist<br>202311.14 awaiting AE recommends<br>2023.11.16 awaiting ElC decision<br>2023.12.4 accept<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=345, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50061907645, createdName=ms4255114797740350, createdTime=Tue Dec 05 10:36:23 CST 2023, time=2023-12-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183765, encodeId=6f9f2183e65b9, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享:兄弟们,中了!!!投稿到接受不到两个月,一篇综述,现在就等见刊!!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5af09148065, createdName=ms7000000774997479, createdTime=Wed Jan 24 22:39:26 CST 2024, time=2024-01-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=914698, encodeId=4ebf91469861, content=投稿命中率:50.0<br>偏重的研究方向:医学<br>经验分享:有好文章赶快投。2021年上4分。2022年上10分。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=456, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1825439058, createdName=鬼混过日子, createdTime=Fri Jan 08 18:50:37 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152059, encodeId=945f215205989, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向:医学<br>经验分享:有没有最近在投的大佬,两轮修稿,已经awaiting EIC decision2个星期了,一般需要多久给最终决定呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/NqoPtUG8c3KoicPDw9ukvZno5y3ibqsdVNWCkwiangfxiaP2pJpicKKPVt393X5eMnkCZicpb6RLhx1ia4du74T91e3ibw/132, createdBy=50932398583, createdName=Jovanny, createdTime=Thu Aug 10 08:42:58 CST 2023, time=2023-08-10, status=1, ipAttribution=上海)]
    2025-08-17 ms7000002977722169 来自北京

    有点惨,期刊官方说中位数78天给结果,我投完苦等,实际超半年才有信儿。
    说我研究方向和期刊要求有点偏差,纯基础分子机制,和临床关联少,直接给我拒了。
    而且现在对数据要求超严,反馈说我原始数据整理得不够清晰规范,另外,投稿格式要严格按官网指南来,我就因为参考文献格式不对还被挑刺了。
    大家投稿前一定要多注意这些还有一些小细节的东西,别像我一样吃亏。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2286522, encodeId=009c22865228c, content=2024.6.8提交初稿,用期刊官网模板排版,参考文献通过 EndNote 导入「Vancouver 格式」,原始数据按「实验分组 - 检测指标 - 重复次数」整理成 Excel 附件<br>6.8-6.15With Editor(编辑初审)7 天收到编辑邮件:确认研究方向符合期刊范畴,数据完整性达标,无需格式修改<br>Under Review(外审)用了20 天<br>系统显示分配2位审稿人<br>7.06Major Revision(大修意见)审稿人1提了3个意见<br>7.22返修准备<br>7.23-7.30Revision Submitted~Under Review返修稿按要求标注修改位置附 1200 字逐点回复信<br>8.17With Editor(编辑终审)<br>期间主动邮件询问进度(模板:简述稿件编号 + 修改亮点 + 礼貌问询),编辑次日回复「正汇总意见」<br>8.19Accept(录用通知)<br>收到录用邮件,附带版面费缴费链接(3295 美元,OA 期刊常规标准), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722175, createdTime=Mon Oct 27 23:28:20 CST 2025, time=2025-10-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2277604, encodeId=ff4f22e760441, content=有点惨,期刊官方说中位数78天给结果,我投完苦等,实际超半年才有信儿。<br>说我研究方向和期刊要求有点偏差,纯基础分子机制,和临床关联少,直接给我拒了。<br>而且现在对数据要求超严,反馈说我原始数据整理得不够清晰规范,另外,投稿格式要严格按官网指南来,我就因为参考文献格式不对还被挑刺了。<br>大家投稿前一定要多注意这些还有一些小细节的东西,别像我一样吃亏。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722169, createdTime=Sun Aug 17 23:09:09 CST 2025, time=2025-08-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2264257, encodeId=2fd0226425eaf, content=有注册账户时,注册账户报错的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18875624576, createdName=ms5000001999881653, createdTime=Fri May 09 22:03:52 CST 2025, time=2025-05-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2265267, encodeId=1a3e226526edd, content=偏重的研究方向:肿瘤<br>经验分享:记录投稿过程 2025.05.08投稿 然后awaiting admin processing 0516 Awaiting Reviewer Selection, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcd68820091, createdName=想要ACCEPT, createdTime=Fri May 16 09:41:11 CST 2025, time=2025-05-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=588271, encodeId=20205882e1d3, content=请问有人最近投稿的嘛??这个杂志是不是很慢,Awaiting Admin Processing这个过程要多久???10天正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=500, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8652460850, createdName=12418dafm09(暂无昵称), createdTime=Mon Apr 06 13:28:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2254202, encodeId=0fdd225420274, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:医学;前沿;医学综合<br>经验分享:1.24投稿, 2.14修回,一个接受,一个小修 修改2周 2.27修改好上传 2.28接受 厉害了我的哥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb5a8346436, createdName=ms8000000905145026, createdTime=Sun Mar 02 11:57:38 CST 2025, time=2025-03-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2173019, encodeId=1ffe21e301990, content=投稿的时候迷茫绝望过,一次次的来到这个地方寻求帮助,现在把投稿过程贴出来,留给需要的人<br>2023.7.21 submit<br>2023.7.24 awaiting reviewer selection<br>2023.7.26 awaiting reviewer invitation<br> awaiting reviewer assignment<br>2023.8.5 awaiting reviewer scores<br>2023.8.9 awaiting AE recommendation<br>2023.8.23 reconsider (re-review) after major revision<br>2023.10.19 submit<br> awaiting admin checklist<br> awaiting reviewer assignment<br>2023.10.31 awaiting admin processing<br> major revision<br>2023.11.7 submit<br> awaiting admin checklist<br>202311.14 awaiting AE recommends<br>2023.11.16 awaiting ElC decision<br>2023.12.4 accept<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=345, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50061907645, createdName=ms4255114797740350, createdTime=Tue Dec 05 10:36:23 CST 2023, time=2023-12-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183765, encodeId=6f9f2183e65b9, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享:兄弟们,中了!!!投稿到接受不到两个月,一篇综述,现在就等见刊!!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5af09148065, createdName=ms7000000774997479, createdTime=Wed Jan 24 22:39:26 CST 2024, time=2024-01-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=914698, encodeId=4ebf91469861, content=投稿命中率:50.0<br>偏重的研究方向:医学<br>经验分享:有好文章赶快投。2021年上4分。2022年上10分。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=456, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1825439058, createdName=鬼混过日子, createdTime=Fri Jan 08 18:50:37 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152059, encodeId=945f215205989, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向:医学<br>经验分享:有没有最近在投的大佬,两轮修稿,已经awaiting EIC decision2个星期了,一般需要多久给最终决定呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/NqoPtUG8c3KoicPDw9ukvZno5y3ibqsdVNWCkwiangfxiaP2pJpicKKPVt393X5eMnkCZicpb6RLhx1ia4du74T91e3ibw/132, createdBy=50932398583, createdName=Jovanny, createdTime=Thu Aug 10 08:42:58 CST 2023, time=2023-08-10, status=1, ipAttribution=上海)]
    2025-05-09 ms5000001999881653 来自北京

    有注册账户时,注册账户报错的吗

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2286522, encodeId=009c22865228c, content=2024.6.8提交初稿,用期刊官网模板排版,参考文献通过 EndNote 导入「Vancouver 格式」,原始数据按「实验分组 - 检测指标 - 重复次数」整理成 Excel 附件<br>6.8-6.15With Editor(编辑初审)7 天收到编辑邮件:确认研究方向符合期刊范畴,数据完整性达标,无需格式修改<br>Under Review(外审)用了20 天<br>系统显示分配2位审稿人<br>7.06Major Revision(大修意见)审稿人1提了3个意见<br>7.22返修准备<br>7.23-7.30Revision Submitted~Under Review返修稿按要求标注修改位置附 1200 字逐点回复信<br>8.17With Editor(编辑终审)<br>期间主动邮件询问进度(模板:简述稿件编号 + 修改亮点 + 礼貌问询),编辑次日回复「正汇总意见」<br>8.19Accept(录用通知)<br>收到录用邮件,附带版面费缴费链接(3295 美元,OA 期刊常规标准), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722175, createdTime=Mon Oct 27 23:28:20 CST 2025, time=2025-10-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2277604, encodeId=ff4f22e760441, content=有点惨,期刊官方说中位数78天给结果,我投完苦等,实际超半年才有信儿。<br>说我研究方向和期刊要求有点偏差,纯基础分子机制,和临床关联少,直接给我拒了。<br>而且现在对数据要求超严,反馈说我原始数据整理得不够清晰规范,另外,投稿格式要严格按官网指南来,我就因为参考文献格式不对还被挑刺了。<br>大家投稿前一定要多注意这些还有一些小细节的东西,别像我一样吃亏。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722169, createdTime=Sun Aug 17 23:09:09 CST 2025, time=2025-08-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2264257, encodeId=2fd0226425eaf, content=有注册账户时,注册账户报错的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18875624576, createdName=ms5000001999881653, createdTime=Fri May 09 22:03:52 CST 2025, time=2025-05-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2265267, encodeId=1a3e226526edd, content=偏重的研究方向:肿瘤<br>经验分享:记录投稿过程 2025.05.08投稿 然后awaiting admin processing 0516 Awaiting Reviewer Selection, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcd68820091, createdName=想要ACCEPT, createdTime=Fri May 16 09:41:11 CST 2025, time=2025-05-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=588271, encodeId=20205882e1d3, content=请问有人最近投稿的嘛??这个杂志是不是很慢,Awaiting Admin Processing这个过程要多久???10天正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=500, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8652460850, createdName=12418dafm09(暂无昵称), createdTime=Mon Apr 06 13:28:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2254202, encodeId=0fdd225420274, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:医学;前沿;医学综合<br>经验分享:1.24投稿, 2.14修回,一个接受,一个小修 修改2周 2.27修改好上传 2.28接受 厉害了我的哥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb5a8346436, createdName=ms8000000905145026, createdTime=Sun Mar 02 11:57:38 CST 2025, time=2025-03-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2173019, encodeId=1ffe21e301990, content=投稿的时候迷茫绝望过,一次次的来到这个地方寻求帮助,现在把投稿过程贴出来,留给需要的人<br>2023.7.21 submit<br>2023.7.24 awaiting reviewer selection<br>2023.7.26 awaiting reviewer invitation<br> awaiting reviewer assignment<br>2023.8.5 awaiting reviewer scores<br>2023.8.9 awaiting AE recommendation<br>2023.8.23 reconsider (re-review) after major revision<br>2023.10.19 submit<br> awaiting admin checklist<br> awaiting reviewer assignment<br>2023.10.31 awaiting admin processing<br> major revision<br>2023.11.7 submit<br> awaiting admin checklist<br>202311.14 awaiting AE recommends<br>2023.11.16 awaiting ElC decision<br>2023.12.4 accept<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=345, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50061907645, createdName=ms4255114797740350, createdTime=Tue Dec 05 10:36:23 CST 2023, time=2023-12-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183765, encodeId=6f9f2183e65b9, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享:兄弟们,中了!!!投稿到接受不到两个月,一篇综述,现在就等见刊!!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5af09148065, createdName=ms7000000774997479, createdTime=Wed Jan 24 22:39:26 CST 2024, time=2024-01-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=914698, encodeId=4ebf91469861, content=投稿命中率:50.0<br>偏重的研究方向:医学<br>经验分享:有好文章赶快投。2021年上4分。2022年上10分。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=456, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1825439058, createdName=鬼混过日子, createdTime=Fri Jan 08 18:50:37 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152059, encodeId=945f215205989, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向:医学<br>经验分享:有没有最近在投的大佬,两轮修稿,已经awaiting EIC decision2个星期了,一般需要多久给最终决定呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/NqoPtUG8c3KoicPDw9ukvZno5y3ibqsdVNWCkwiangfxiaP2pJpicKKPVt393X5eMnkCZicpb6RLhx1ia4du74T91e3ibw/132, createdBy=50932398583, createdName=Jovanny, createdTime=Thu Aug 10 08:42:58 CST 2023, time=2023-08-10, status=1, ipAttribution=上海)]
    2025-05-16 想要ACCEPT 来自江苏省

    偏重的研究方向:肿瘤
    经验分享:记录投稿过程 2025.05.08投稿 然后awaiting admin processing 0516 Awaiting Reviewer Selection

    3

    展开3条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2286522, encodeId=009c22865228c, content=2024.6.8提交初稿,用期刊官网模板排版,参考文献通过 EndNote 导入「Vancouver 格式」,原始数据按「实验分组 - 检测指标 - 重复次数」整理成 Excel 附件<br>6.8-6.15With Editor(编辑初审)7 天收到编辑邮件:确认研究方向符合期刊范畴,数据完整性达标,无需格式修改<br>Under Review(外审)用了20 天<br>系统显示分配2位审稿人<br>7.06Major Revision(大修意见)审稿人1提了3个意见<br>7.22返修准备<br>7.23-7.30Revision Submitted~Under Review返修稿按要求标注修改位置附 1200 字逐点回复信<br>8.17With Editor(编辑终审)<br>期间主动邮件询问进度(模板:简述稿件编号 + 修改亮点 + 礼貌问询),编辑次日回复「正汇总意见」<br>8.19Accept(录用通知)<br>收到录用邮件,附带版面费缴费链接(3295 美元,OA 期刊常规标准), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722175, createdTime=Mon Oct 27 23:28:20 CST 2025, time=2025-10-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2277604, encodeId=ff4f22e760441, content=有点惨,期刊官方说中位数78天给结果,我投完苦等,实际超半年才有信儿。<br>说我研究方向和期刊要求有点偏差,纯基础分子机制,和临床关联少,直接给我拒了。<br>而且现在对数据要求超严,反馈说我原始数据整理得不够清晰规范,另外,投稿格式要严格按官网指南来,我就因为参考文献格式不对还被挑刺了。<br>大家投稿前一定要多注意这些还有一些小细节的东西,别像我一样吃亏。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722169, createdTime=Sun Aug 17 23:09:09 CST 2025, time=2025-08-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2264257, encodeId=2fd0226425eaf, content=有注册账户时,注册账户报错的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18875624576, createdName=ms5000001999881653, createdTime=Fri May 09 22:03:52 CST 2025, time=2025-05-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2265267, encodeId=1a3e226526edd, content=偏重的研究方向:肿瘤<br>经验分享:记录投稿过程 2025.05.08投稿 然后awaiting admin processing 0516 Awaiting Reviewer Selection, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcd68820091, createdName=想要ACCEPT, createdTime=Fri May 16 09:41:11 CST 2025, time=2025-05-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=588271, encodeId=20205882e1d3, content=请问有人最近投稿的嘛??这个杂志是不是很慢,Awaiting Admin Processing这个过程要多久???10天正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=500, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8652460850, createdName=12418dafm09(暂无昵称), createdTime=Mon Apr 06 13:28:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2254202, encodeId=0fdd225420274, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:医学;前沿;医学综合<br>经验分享:1.24投稿, 2.14修回,一个接受,一个小修 修改2周 2.27修改好上传 2.28接受 厉害了我的哥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb5a8346436, createdName=ms8000000905145026, createdTime=Sun Mar 02 11:57:38 CST 2025, time=2025-03-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2173019, encodeId=1ffe21e301990, content=投稿的时候迷茫绝望过,一次次的来到这个地方寻求帮助,现在把投稿过程贴出来,留给需要的人<br>2023.7.21 submit<br>2023.7.24 awaiting reviewer selection<br>2023.7.26 awaiting reviewer invitation<br> awaiting reviewer assignment<br>2023.8.5 awaiting reviewer scores<br>2023.8.9 awaiting AE recommendation<br>2023.8.23 reconsider (re-review) after major revision<br>2023.10.19 submit<br> awaiting admin checklist<br> awaiting reviewer assignment<br>2023.10.31 awaiting admin processing<br> major revision<br>2023.11.7 submit<br> awaiting admin checklist<br>202311.14 awaiting AE recommends<br>2023.11.16 awaiting ElC decision<br>2023.12.4 accept<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=345, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50061907645, createdName=ms4255114797740350, createdTime=Tue Dec 05 10:36:23 CST 2023, time=2023-12-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183765, encodeId=6f9f2183e65b9, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享:兄弟们,中了!!!投稿到接受不到两个月,一篇综述,现在就等见刊!!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5af09148065, createdName=ms7000000774997479, createdTime=Wed Jan 24 22:39:26 CST 2024, time=2024-01-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=914698, encodeId=4ebf91469861, content=投稿命中率:50.0<br>偏重的研究方向:医学<br>经验分享:有好文章赶快投。2021年上4分。2022年上10分。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=456, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1825439058, createdName=鬼混过日子, createdTime=Fri Jan 08 18:50:37 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152059, encodeId=945f215205989, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向:医学<br>经验分享:有没有最近在投的大佬,两轮修稿,已经awaiting EIC decision2个星期了,一般需要多久给最终决定呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/NqoPtUG8c3KoicPDw9ukvZno5y3ibqsdVNWCkwiangfxiaP2pJpicKKPVt393X5eMnkCZicpb6RLhx1ia4du74T91e3ibw/132, createdBy=50932398583, createdName=Jovanny, createdTime=Thu Aug 10 08:42:58 CST 2023, time=2023-08-10, status=1, ipAttribution=上海)]
    2020-04-06 12418dafm09(暂无昵称)

    请问有人最近投稿的嘛??这个杂志是不是很慢,Awaiting Admin Processing这个过程要多久???10天正常吗

    7

    展开7条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2286522, encodeId=009c22865228c, content=2024.6.8提交初稿,用期刊官网模板排版,参考文献通过 EndNote 导入「Vancouver 格式」,原始数据按「实验分组 - 检测指标 - 重复次数」整理成 Excel 附件<br>6.8-6.15With Editor(编辑初审)7 天收到编辑邮件:确认研究方向符合期刊范畴,数据完整性达标,无需格式修改<br>Under Review(外审)用了20 天<br>系统显示分配2位审稿人<br>7.06Major Revision(大修意见)审稿人1提了3个意见<br>7.22返修准备<br>7.23-7.30Revision Submitted~Under Review返修稿按要求标注修改位置附 1200 字逐点回复信<br>8.17With Editor(编辑终审)<br>期间主动邮件询问进度(模板:简述稿件编号 + 修改亮点 + 礼貌问询),编辑次日回复「正汇总意见」<br>8.19Accept(录用通知)<br>收到录用邮件,附带版面费缴费链接(3295 美元,OA 期刊常规标准), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722175, createdTime=Mon Oct 27 23:28:20 CST 2025, time=2025-10-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2277604, encodeId=ff4f22e760441, content=有点惨,期刊官方说中位数78天给结果,我投完苦等,实际超半年才有信儿。<br>说我研究方向和期刊要求有点偏差,纯基础分子机制,和临床关联少,直接给我拒了。<br>而且现在对数据要求超严,反馈说我原始数据整理得不够清晰规范,另外,投稿格式要严格按官网指南来,我就因为参考文献格式不对还被挑刺了。<br>大家投稿前一定要多注意这些还有一些小细节的东西,别像我一样吃亏。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722169, createdTime=Sun Aug 17 23:09:09 CST 2025, time=2025-08-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2264257, encodeId=2fd0226425eaf, content=有注册账户时,注册账户报错的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18875624576, createdName=ms5000001999881653, createdTime=Fri May 09 22:03:52 CST 2025, time=2025-05-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2265267, encodeId=1a3e226526edd, content=偏重的研究方向:肿瘤<br>经验分享:记录投稿过程 2025.05.08投稿 然后awaiting admin processing 0516 Awaiting Reviewer Selection, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcd68820091, createdName=想要ACCEPT, createdTime=Fri May 16 09:41:11 CST 2025, time=2025-05-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=588271, encodeId=20205882e1d3, content=请问有人最近投稿的嘛??这个杂志是不是很慢,Awaiting Admin Processing这个过程要多久???10天正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=500, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8652460850, createdName=12418dafm09(暂无昵称), createdTime=Mon Apr 06 13:28:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2254202, encodeId=0fdd225420274, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:医学;前沿;医学综合<br>经验分享:1.24投稿, 2.14修回,一个接受,一个小修 修改2周 2.27修改好上传 2.28接受 厉害了我的哥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb5a8346436, createdName=ms8000000905145026, createdTime=Sun Mar 02 11:57:38 CST 2025, time=2025-03-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2173019, encodeId=1ffe21e301990, content=投稿的时候迷茫绝望过,一次次的来到这个地方寻求帮助,现在把投稿过程贴出来,留给需要的人<br>2023.7.21 submit<br>2023.7.24 awaiting reviewer selection<br>2023.7.26 awaiting reviewer invitation<br> awaiting reviewer assignment<br>2023.8.5 awaiting reviewer scores<br>2023.8.9 awaiting AE recommendation<br>2023.8.23 reconsider (re-review) after major revision<br>2023.10.19 submit<br> awaiting admin checklist<br> awaiting reviewer assignment<br>2023.10.31 awaiting admin processing<br> major revision<br>2023.11.7 submit<br> awaiting admin checklist<br>202311.14 awaiting AE recommends<br>2023.11.16 awaiting ElC decision<br>2023.12.4 accept<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=345, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50061907645, createdName=ms4255114797740350, createdTime=Tue Dec 05 10:36:23 CST 2023, time=2023-12-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183765, encodeId=6f9f2183e65b9, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享:兄弟们,中了!!!投稿到接受不到两个月,一篇综述,现在就等见刊!!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5af09148065, createdName=ms7000000774997479, createdTime=Wed Jan 24 22:39:26 CST 2024, time=2024-01-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=914698, encodeId=4ebf91469861, content=投稿命中率:50.0<br>偏重的研究方向:医学<br>经验分享:有好文章赶快投。2021年上4分。2022年上10分。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=456, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1825439058, createdName=鬼混过日子, createdTime=Fri Jan 08 18:50:37 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152059, encodeId=945f215205989, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向:医学<br>经验分享:有没有最近在投的大佬,两轮修稿,已经awaiting EIC decision2个星期了,一般需要多久给最终决定呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/NqoPtUG8c3KoicPDw9ukvZno5y3ibqsdVNWCkwiangfxiaP2pJpicKKPVt393X5eMnkCZicpb6RLhx1ia4du74T91e3ibw/132, createdBy=50932398583, createdName=Jovanny, createdTime=Thu Aug 10 08:42:58 CST 2023, time=2023-08-10, status=1, ipAttribution=上海)]
    2025-03-02 ms8000000905145026 来自北京

    审稿速度:1.0 | 投稿命中率:95.0
    偏重的研究方向:医学;前沿;医学综合
    经验分享:1.24投稿, 2.14修回,一个接受,一个小修 修改2周 2.27修改好上传 2.28接受 厉害了我的哥

    1

    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2286522, encodeId=009c22865228c, content=2024.6.8提交初稿,用期刊官网模板排版,参考文献通过 EndNote 导入「Vancouver 格式」,原始数据按「实验分组 - 检测指标 - 重复次数」整理成 Excel 附件<br>6.8-6.15With Editor(编辑初审)7 天收到编辑邮件:确认研究方向符合期刊范畴,数据完整性达标,无需格式修改<br>Under Review(外审)用了20 天<br>系统显示分配2位审稿人<br>7.06Major Revision(大修意见)审稿人1提了3个意见<br>7.22返修准备<br>7.23-7.30Revision Submitted~Under Review返修稿按要求标注修改位置附 1200 字逐点回复信<br>8.17With Editor(编辑终审)<br>期间主动邮件询问进度(模板:简述稿件编号 + 修改亮点 + 礼貌问询),编辑次日回复「正汇总意见」<br>8.19Accept(录用通知)<br>收到录用邮件,附带版面费缴费链接(3295 美元,OA 期刊常规标准), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722175, createdTime=Mon Oct 27 23:28:20 CST 2025, time=2025-10-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2277604, encodeId=ff4f22e760441, content=有点惨,期刊官方说中位数78天给结果,我投完苦等,实际超半年才有信儿。<br>说我研究方向和期刊要求有点偏差,纯基础分子机制,和临床关联少,直接给我拒了。<br>而且现在对数据要求超严,反馈说我原始数据整理得不够清晰规范,另外,投稿格式要严格按官网指南来,我就因为参考文献格式不对还被挑刺了。<br>大家投稿前一定要多注意这些还有一些小细节的东西,别像我一样吃亏。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722169, createdTime=Sun Aug 17 23:09:09 CST 2025, time=2025-08-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2264257, encodeId=2fd0226425eaf, content=有注册账户时,注册账户报错的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18875624576, createdName=ms5000001999881653, createdTime=Fri May 09 22:03:52 CST 2025, time=2025-05-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2265267, encodeId=1a3e226526edd, content=偏重的研究方向:肿瘤<br>经验分享:记录投稿过程 2025.05.08投稿 然后awaiting admin processing 0516 Awaiting Reviewer Selection, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcd68820091, createdName=想要ACCEPT, createdTime=Fri May 16 09:41:11 CST 2025, time=2025-05-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=588271, encodeId=20205882e1d3, content=请问有人最近投稿的嘛??这个杂志是不是很慢,Awaiting Admin Processing这个过程要多久???10天正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=500, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8652460850, createdName=12418dafm09(暂无昵称), createdTime=Mon Apr 06 13:28:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2254202, encodeId=0fdd225420274, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:医学;前沿;医学综合<br>经验分享:1.24投稿, 2.14修回,一个接受,一个小修 修改2周 2.27修改好上传 2.28接受 厉害了我的哥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb5a8346436, createdName=ms8000000905145026, createdTime=Sun Mar 02 11:57:38 CST 2025, time=2025-03-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2173019, encodeId=1ffe21e301990, content=投稿的时候迷茫绝望过,一次次的来到这个地方寻求帮助,现在把投稿过程贴出来,留给需要的人<br>2023.7.21 submit<br>2023.7.24 awaiting reviewer selection<br>2023.7.26 awaiting reviewer invitation<br> awaiting reviewer assignment<br>2023.8.5 awaiting reviewer scores<br>2023.8.9 awaiting AE recommendation<br>2023.8.23 reconsider (re-review) after major revision<br>2023.10.19 submit<br> awaiting admin checklist<br> awaiting reviewer assignment<br>2023.10.31 awaiting admin processing<br> major revision<br>2023.11.7 submit<br> awaiting admin checklist<br>202311.14 awaiting AE recommends<br>2023.11.16 awaiting ElC decision<br>2023.12.4 accept<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=345, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50061907645, createdName=ms4255114797740350, createdTime=Tue Dec 05 10:36:23 CST 2023, time=2023-12-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183765, encodeId=6f9f2183e65b9, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享:兄弟们,中了!!!投稿到接受不到两个月,一篇综述,现在就等见刊!!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5af09148065, createdName=ms7000000774997479, createdTime=Wed Jan 24 22:39:26 CST 2024, time=2024-01-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=914698, encodeId=4ebf91469861, content=投稿命中率:50.0<br>偏重的研究方向:医学<br>经验分享:有好文章赶快投。2021年上4分。2022年上10分。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=456, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1825439058, createdName=鬼混过日子, createdTime=Fri Jan 08 18:50:37 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152059, encodeId=945f215205989, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向:医学<br>经验分享:有没有最近在投的大佬,两轮修稿,已经awaiting EIC decision2个星期了,一般需要多久给最终决定呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/NqoPtUG8c3KoicPDw9ukvZno5y3ibqsdVNWCkwiangfxiaP2pJpicKKPVt393X5eMnkCZicpb6RLhx1ia4du74T91e3ibw/132, createdBy=50932398583, createdName=Jovanny, createdTime=Thu Aug 10 08:42:58 CST 2023, time=2023-08-10, status=1, ipAttribution=上海)]
    2023-12-05 ms4255114797740350 来自北京

    投稿的时候迷茫绝望过,一次次的来到这个地方寻求帮助,现在把投稿过程贴出来,留给需要的人
    2023.7.21 submit
    2023.7.24 awaiting reviewer selection
    2023.7.26 awaiting reviewer invitation
    awaiting reviewer assignment
    2023.8.5 awaiting reviewer scores
    2023.8.9 awaiting AE recommendation
    2023.8.23 reconsider (re-review) after major revision
    2023.10.19 submit
    awaiting admin checklist
    awaiting reviewer assignment
    2023.10.31 awaiting admin processing
    major revision
    2023.11.7 submit
    awaiting admin checklist
    202311.14 awaiting AE recommends
    2023.11.16 awaiting ElC decision
    2023.12.4 accept

    21

    展开21条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2286522, encodeId=009c22865228c, content=2024.6.8提交初稿,用期刊官网模板排版,参考文献通过 EndNote 导入「Vancouver 格式」,原始数据按「实验分组 - 检测指标 - 重复次数」整理成 Excel 附件<br>6.8-6.15With Editor(编辑初审)7 天收到编辑邮件:确认研究方向符合期刊范畴,数据完整性达标,无需格式修改<br>Under Review(外审)用了20 天<br>系统显示分配2位审稿人<br>7.06Major Revision(大修意见)审稿人1提了3个意见<br>7.22返修准备<br>7.23-7.30Revision Submitted~Under Review返修稿按要求标注修改位置附 1200 字逐点回复信<br>8.17With Editor(编辑终审)<br>期间主动邮件询问进度(模板:简述稿件编号 + 修改亮点 + 礼貌问询),编辑次日回复「正汇总意见」<br>8.19Accept(录用通知)<br>收到录用邮件,附带版面费缴费链接(3295 美元,OA 期刊常规标准), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722175, createdTime=Mon Oct 27 23:28:20 CST 2025, time=2025-10-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2277604, encodeId=ff4f22e760441, content=有点惨,期刊官方说中位数78天给结果,我投完苦等,实际超半年才有信儿。<br>说我研究方向和期刊要求有点偏差,纯基础分子机制,和临床关联少,直接给我拒了。<br>而且现在对数据要求超严,反馈说我原始数据整理得不够清晰规范,另外,投稿格式要严格按官网指南来,我就因为参考文献格式不对还被挑刺了。<br>大家投稿前一定要多注意这些还有一些小细节的东西,别像我一样吃亏。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722169, createdTime=Sun Aug 17 23:09:09 CST 2025, time=2025-08-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2264257, encodeId=2fd0226425eaf, content=有注册账户时,注册账户报错的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18875624576, createdName=ms5000001999881653, createdTime=Fri May 09 22:03:52 CST 2025, time=2025-05-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2265267, encodeId=1a3e226526edd, content=偏重的研究方向:肿瘤<br>经验分享:记录投稿过程 2025.05.08投稿 然后awaiting admin processing 0516 Awaiting Reviewer Selection, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcd68820091, createdName=想要ACCEPT, createdTime=Fri May 16 09:41:11 CST 2025, time=2025-05-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=588271, encodeId=20205882e1d3, content=请问有人最近投稿的嘛??这个杂志是不是很慢,Awaiting Admin Processing这个过程要多久???10天正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=500, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8652460850, createdName=12418dafm09(暂无昵称), createdTime=Mon Apr 06 13:28:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2254202, encodeId=0fdd225420274, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:医学;前沿;医学综合<br>经验分享:1.24投稿, 2.14修回,一个接受,一个小修 修改2周 2.27修改好上传 2.28接受 厉害了我的哥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb5a8346436, createdName=ms8000000905145026, createdTime=Sun Mar 02 11:57:38 CST 2025, time=2025-03-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2173019, encodeId=1ffe21e301990, content=投稿的时候迷茫绝望过,一次次的来到这个地方寻求帮助,现在把投稿过程贴出来,留给需要的人<br>2023.7.21 submit<br>2023.7.24 awaiting reviewer selection<br>2023.7.26 awaiting reviewer invitation<br> awaiting reviewer assignment<br>2023.8.5 awaiting reviewer scores<br>2023.8.9 awaiting AE recommendation<br>2023.8.23 reconsider (re-review) after major revision<br>2023.10.19 submit<br> awaiting admin checklist<br> awaiting reviewer assignment<br>2023.10.31 awaiting admin processing<br> major revision<br>2023.11.7 submit<br> awaiting admin checklist<br>202311.14 awaiting AE recommends<br>2023.11.16 awaiting ElC decision<br>2023.12.4 accept<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=345, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50061907645, createdName=ms4255114797740350, createdTime=Tue Dec 05 10:36:23 CST 2023, time=2023-12-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183765, encodeId=6f9f2183e65b9, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享:兄弟们,中了!!!投稿到接受不到两个月,一篇综述,现在就等见刊!!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5af09148065, createdName=ms7000000774997479, createdTime=Wed Jan 24 22:39:26 CST 2024, time=2024-01-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=914698, encodeId=4ebf91469861, content=投稿命中率:50.0<br>偏重的研究方向:医学<br>经验分享:有好文章赶快投。2021年上4分。2022年上10分。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=456, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1825439058, createdName=鬼混过日子, createdTime=Fri Jan 08 18:50:37 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152059, encodeId=945f215205989, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向:医学<br>经验分享:有没有最近在投的大佬,两轮修稿,已经awaiting EIC decision2个星期了,一般需要多久给最终决定呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/NqoPtUG8c3KoicPDw9ukvZno5y3ibqsdVNWCkwiangfxiaP2pJpicKKPVt393X5eMnkCZicpb6RLhx1ia4du74T91e3ibw/132, createdBy=50932398583, createdName=Jovanny, createdTime=Thu Aug 10 08:42:58 CST 2023, time=2023-08-10, status=1, ipAttribution=上海)]
    2024-01-24 ms7000000774997479 来自上海

    审稿速度:1.0 | 投稿命中率:95.0
    经验分享:兄弟们,中了!!!投稿到接受不到两个月,一篇综述,现在就等见刊!!!

    5

    展开5条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2286522, encodeId=009c22865228c, content=2024.6.8提交初稿,用期刊官网模板排版,参考文献通过 EndNote 导入「Vancouver 格式」,原始数据按「实验分组 - 检测指标 - 重复次数」整理成 Excel 附件<br>6.8-6.15With Editor(编辑初审)7 天收到编辑邮件:确认研究方向符合期刊范畴,数据完整性达标,无需格式修改<br>Under Review(外审)用了20 天<br>系统显示分配2位审稿人<br>7.06Major Revision(大修意见)审稿人1提了3个意见<br>7.22返修准备<br>7.23-7.30Revision Submitted~Under Review返修稿按要求标注修改位置附 1200 字逐点回复信<br>8.17With Editor(编辑终审)<br>期间主动邮件询问进度(模板:简述稿件编号 + 修改亮点 + 礼貌问询),编辑次日回复「正汇总意见」<br>8.19Accept(录用通知)<br>收到录用邮件,附带版面费缴费链接(3295 美元,OA 期刊常规标准), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722175, createdTime=Mon Oct 27 23:28:20 CST 2025, time=2025-10-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2277604, encodeId=ff4f22e760441, content=有点惨,期刊官方说中位数78天给结果,我投完苦等,实际超半年才有信儿。<br>说我研究方向和期刊要求有点偏差,纯基础分子机制,和临床关联少,直接给我拒了。<br>而且现在对数据要求超严,反馈说我原始数据整理得不够清晰规范,另外,投稿格式要严格按官网指南来,我就因为参考文献格式不对还被挑刺了。<br>大家投稿前一定要多注意这些还有一些小细节的东西,别像我一样吃亏。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722169, createdTime=Sun Aug 17 23:09:09 CST 2025, time=2025-08-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2264257, encodeId=2fd0226425eaf, content=有注册账户时,注册账户报错的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18875624576, createdName=ms5000001999881653, createdTime=Fri May 09 22:03:52 CST 2025, time=2025-05-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2265267, encodeId=1a3e226526edd, content=偏重的研究方向:肿瘤<br>经验分享:记录投稿过程 2025.05.08投稿 然后awaiting admin processing 0516 Awaiting Reviewer Selection, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcd68820091, createdName=想要ACCEPT, createdTime=Fri May 16 09:41:11 CST 2025, time=2025-05-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=588271, encodeId=20205882e1d3, content=请问有人最近投稿的嘛??这个杂志是不是很慢,Awaiting Admin Processing这个过程要多久???10天正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=500, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8652460850, createdName=12418dafm09(暂无昵称), createdTime=Mon Apr 06 13:28:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2254202, encodeId=0fdd225420274, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:医学;前沿;医学综合<br>经验分享:1.24投稿, 2.14修回,一个接受,一个小修 修改2周 2.27修改好上传 2.28接受 厉害了我的哥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb5a8346436, createdName=ms8000000905145026, createdTime=Sun Mar 02 11:57:38 CST 2025, time=2025-03-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2173019, encodeId=1ffe21e301990, content=投稿的时候迷茫绝望过,一次次的来到这个地方寻求帮助,现在把投稿过程贴出来,留给需要的人<br>2023.7.21 submit<br>2023.7.24 awaiting reviewer selection<br>2023.7.26 awaiting reviewer invitation<br> awaiting reviewer assignment<br>2023.8.5 awaiting reviewer scores<br>2023.8.9 awaiting AE recommendation<br>2023.8.23 reconsider (re-review) after major revision<br>2023.10.19 submit<br> awaiting admin checklist<br> awaiting reviewer assignment<br>2023.10.31 awaiting admin processing<br> major revision<br>2023.11.7 submit<br> awaiting admin checklist<br>202311.14 awaiting AE recommends<br>2023.11.16 awaiting ElC decision<br>2023.12.4 accept<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=345, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50061907645, createdName=ms4255114797740350, createdTime=Tue Dec 05 10:36:23 CST 2023, time=2023-12-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183765, encodeId=6f9f2183e65b9, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享:兄弟们,中了!!!投稿到接受不到两个月,一篇综述,现在就等见刊!!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5af09148065, createdName=ms7000000774997479, createdTime=Wed Jan 24 22:39:26 CST 2024, time=2024-01-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=914698, encodeId=4ebf91469861, content=投稿命中率:50.0<br>偏重的研究方向:医学<br>经验分享:有好文章赶快投。2021年上4分。2022年上10分。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=456, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1825439058, createdName=鬼混过日子, createdTime=Fri Jan 08 18:50:37 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152059, encodeId=945f215205989, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向:医学<br>经验分享:有没有最近在投的大佬,两轮修稿,已经awaiting EIC decision2个星期了,一般需要多久给最终决定呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/NqoPtUG8c3KoicPDw9ukvZno5y3ibqsdVNWCkwiangfxiaP2pJpicKKPVt393X5eMnkCZicpb6RLhx1ia4du74T91e3ibw/132, createdBy=50932398583, createdName=Jovanny, createdTime=Thu Aug 10 08:42:58 CST 2023, time=2023-08-10, status=1, ipAttribution=上海)]
    2021-01-08 鬼混过日子

    投稿命中率:50.0
    偏重的研究方向:医学
    经验分享:有好文章赶快投。2021年上4分。2022年上10分。

    7

    展开7条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2286522, encodeId=009c22865228c, content=2024.6.8提交初稿,用期刊官网模板排版,参考文献通过 EndNote 导入「Vancouver 格式」,原始数据按「实验分组 - 检测指标 - 重复次数」整理成 Excel 附件<br>6.8-6.15With Editor(编辑初审)7 天收到编辑邮件:确认研究方向符合期刊范畴,数据完整性达标,无需格式修改<br>Under Review(外审)用了20 天<br>系统显示分配2位审稿人<br>7.06Major Revision(大修意见)审稿人1提了3个意见<br>7.22返修准备<br>7.23-7.30Revision Submitted~Under Review返修稿按要求标注修改位置附 1200 字逐点回复信<br>8.17With Editor(编辑终审)<br>期间主动邮件询问进度(模板:简述稿件编号 + 修改亮点 + 礼貌问询),编辑次日回复「正汇总意见」<br>8.19Accept(录用通知)<br>收到录用邮件,附带版面费缴费链接(3295 美元,OA 期刊常规标准), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722175, createdTime=Mon Oct 27 23:28:20 CST 2025, time=2025-10-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2277604, encodeId=ff4f22e760441, content=有点惨,期刊官方说中位数78天给结果,我投完苦等,实际超半年才有信儿。<br>说我研究方向和期刊要求有点偏差,纯基础分子机制,和临床关联少,直接给我拒了。<br>而且现在对数据要求超严,反馈说我原始数据整理得不够清晰规范,另外,投稿格式要严格按官网指南来,我就因为参考文献格式不对还被挑刺了。<br>大家投稿前一定要多注意这些还有一些小细节的东西,别像我一样吃亏。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722169, createdTime=Sun Aug 17 23:09:09 CST 2025, time=2025-08-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2264257, encodeId=2fd0226425eaf, content=有注册账户时,注册账户报错的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18875624576, createdName=ms5000001999881653, createdTime=Fri May 09 22:03:52 CST 2025, time=2025-05-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2265267, encodeId=1a3e226526edd, content=偏重的研究方向:肿瘤<br>经验分享:记录投稿过程 2025.05.08投稿 然后awaiting admin processing 0516 Awaiting Reviewer Selection, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcd68820091, createdName=想要ACCEPT, createdTime=Fri May 16 09:41:11 CST 2025, time=2025-05-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=588271, encodeId=20205882e1d3, content=请问有人最近投稿的嘛??这个杂志是不是很慢,Awaiting Admin Processing这个过程要多久???10天正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=500, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8652460850, createdName=12418dafm09(暂无昵称), createdTime=Mon Apr 06 13:28:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2254202, encodeId=0fdd225420274, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:医学;前沿;医学综合<br>经验分享:1.24投稿, 2.14修回,一个接受,一个小修 修改2周 2.27修改好上传 2.28接受 厉害了我的哥, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb5a8346436, createdName=ms8000000905145026, createdTime=Sun Mar 02 11:57:38 CST 2025, time=2025-03-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2173019, encodeId=1ffe21e301990, content=投稿的时候迷茫绝望过,一次次的来到这个地方寻求帮助,现在把投稿过程贴出来,留给需要的人<br>2023.7.21 submit<br>2023.7.24 awaiting reviewer selection<br>2023.7.26 awaiting reviewer invitation<br> awaiting reviewer assignment<br>2023.8.5 awaiting reviewer scores<br>2023.8.9 awaiting AE recommendation<br>2023.8.23 reconsider (re-review) after major revision<br>2023.10.19 submit<br> awaiting admin checklist<br> awaiting reviewer assignment<br>2023.10.31 awaiting admin processing<br> major revision<br>2023.11.7 submit<br> awaiting admin checklist<br>202311.14 awaiting AE recommends<br>2023.11.16 awaiting ElC decision<br>2023.12.4 accept<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=345, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50061907645, createdName=ms4255114797740350, createdTime=Tue Dec 05 10:36:23 CST 2023, time=2023-12-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183765, encodeId=6f9f2183e65b9, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享:兄弟们,中了!!!投稿到接受不到两个月,一篇综述,现在就等见刊!!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5af09148065, createdName=ms7000000774997479, createdTime=Wed Jan 24 22:39:26 CST 2024, time=2024-01-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=914698, encodeId=4ebf91469861, content=投稿命中率:50.0<br>偏重的研究方向:医学<br>经验分享:有好文章赶快投。2021年上4分。2022年上10分。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=456, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1825439058, createdName=鬼混过日子, createdTime=Fri Jan 08 18:50:37 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152059, encodeId=945f215205989, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向:医学<br>经验分享:有没有最近在投的大佬,两轮修稿,已经awaiting EIC decision2个星期了,一般需要多久给最终决定呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/NqoPtUG8c3KoicPDw9ukvZno5y3ibqsdVNWCkwiangfxiaP2pJpicKKPVt393X5eMnkCZicpb6RLhx1ia4du74T91e3ibw/132, createdBy=50932398583, createdName=Jovanny, createdTime=Thu Aug 10 08:42:58 CST 2023, time=2023-08-10, status=1, ipAttribution=上海)]
    2023-08-10 Jovanny 来自上海

    审稿速度:2.0 | 投稿命中率:5.0
    偏重的研究方向:医学
    经验分享:有没有最近在投的大佬,两轮修稿,已经awaiting EIC decision2个星期了,一般需要多久给最终决定呀

    4

    展开4条回复
共192条页码: 1/20页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分